Cargando…

Postoperative Recovery of Visual Function after Macula-Off Rhegmatogenous Retinal Detachment

PURPOSE: To determine which factors affect the recovery of visual function in macula off rhegmatogenous retinal detachment (RRD). METHODS: In a prospective study of forty-five patients with a primary macula-off RRD of 24 hours to 6 weeks duration, the height of the macular detachment was determined...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Put, Mathijs A. J., Croonen, Danna, Nolte, Ilja M., Japing, Wouter J., Hooymans, Johanna M. M., Los, Leonoor I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057275/
https://www.ncbi.nlm.nih.gov/pubmed/24927502
http://dx.doi.org/10.1371/journal.pone.0099787
Descripción
Sumario:PURPOSE: To determine which factors affect the recovery of visual function in macula off rhegmatogenous retinal detachment (RRD). METHODS: In a prospective study of forty-five patients with a primary macula-off RRD of 24 hours to 6 weeks duration, the height of the macular detachment was determined by ultrasonography. At 12 months postoperatively, best corrected visual acuity (BCVA), contrast acuity, and color confusion indexes (CCI) were obtained. RESULTS: Macular detachment was present for 2–32 (median 7) days before repair. A shorter duration of macular detachment was correlated with a better CCI saturé (p = 0.0026) and lower LogMAR BCVA (better Snellen visual acuity)(p = 0.012). Also, a smaller height of macular detachment was correlated with a lower LogMAR BCVA (p = 0.0034). A younger age and lower pre-operative LogMAR BCVA at presentation were both correlated with better postoperative contrast acuity in the total group (age: p = 1.7×10(−4) and pre-operative LogMAR BCVA: p = 0.0034). CONCLUSION: Functional recovery after macula-off RRD is affected by the duration and the height of the macular detachment. Recovery of contrast acuity is also affected by age and BCVA at presentation. MEETING PRESENTATION: ARVO annual meeting 2013, May 7, Seattle, Washington, United States of America. TRIAL REGISTRATION: trialregister.nl NTR839